Best of ASCO - 2014 Annual Meeting

 

Welcome

Bone Tumors

Sarcoma

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A comparison of outcomes, presentation, and treatment in pediatric (Ped) versus adult patients (Pts) with Ewing sarcoma.

Eric B Schwartz

11528

Adult osteosarcoma experience in a cancer center in Mexico.

Jackeline Grace Lara Campos

e23504

An observational, multicenter, retrospective, Italian Sarcoma Group (ISG) study of trabectedin in patients with advanced soft tissue sarcoma (STS).

Emanuela Palmerini

e23502

Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: An open label phase 2 clinical trial.

Lu Xie

11520

Can DNA methylation patterns be used as predictive biomarkers for chemotherapy response in osteosarcoma?

Sarbajit Mukherjee

11525

Comprehensive genomic profiling of sarcomas in Chinese population.

Jie Lin

11526

Detection of autoantibodies against alpha-enolase (ENO1) as potential biomarkers improving immunodiagnosis in human osteosarcoma by serological proteome analysis.

Jitian Li

e23506

Drug repurposing as a source of innovative therapies in osteosarcoma.

Gauthier Bouche

11524

Efficacy and safety of lurbinectedin (PM1183) in Ewing sarcoma: Final results from a phase 2 study.

Vivek Subbiah

11519

Genome and transcriptome profiling of relapsed and metastatic osteosarcoma.

Chia Chin Wu

11522

More effective systemic therapies are needed for chondrosarcoma: A National Cancer Data Base (NCDB) analysis.

Karen M Xu

e23508

Neoadjuvant denosumab for the treatment of resectable giant cell tumor of bone: First results of Russian multicenter study.

Alexander A. Fedenko

11521

Pazopanib in metastatic osteosarcoma patients: Report of 9 cases treated off label at Rizzoli Orthopedic Institute.

Alessandra Longhi

e23501

Promotion of proliferation and inhibition of apoptosis by diacylglycerol kinase zeta, a potential oncogene of osteosarcoma

Wenxi Yu

e23503

Rare bone sarcoma: A retrospective analysis of 149 adult patients from the French Sarcoma Group.

Pascaline Boudou-Rouquette

11523

Response to apatinib in patients with osteosarcoma: Updated evidence of efficacy and safety.

Chongqi Tu

e23500

Results of randomized, placebo (PL)-controlled phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer.

Florence Duffaud

11504

Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma (OS).

Nathalie Gaspar

11527

The clinical significance of the detection of chemotherapy drug sensitivity in patients with osteosarcoma and soft tissue sarcoma.

Qianrong Wang

e23505